Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Inovio Pharmaceuticals, Inc. (INO)

Add INO Price Alert      Hide Sticky   Hide Intro
Moderator: Ubertino, TomP1
Search This Board: 
Last Post: 7/20/2017 5:12:18 PM - Followers: 413 - Board type: Free - Posts Today: 0

Logo: Inovio

ebruary 12, 2014 Inovio CEO Dr. Joseph Kim rings bell to open trading on NYSE-

Float: 97.65 M

Shares Outstanding: 127.26 M

Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company?s SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. Inovio?s proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. The company also has access to formulation and manufacturing expertise, and technology through its controlling ownership in VGX International. Inovio?s clinical programs include trials for HPV/cervical cancer (therapeutic) and HIV vaccines; and an IND has been filed for an avian influenza vaccine. Its partners and collaborators include Roche,Merck, Tripep, University of Southampton, University of Pennsylvania, HIV Vaccines Trial Network, and National Microbiology Laboratory of the Public Health Agency of Canada. The company was formerly known as Genetronics Biomedical Corp. and changed its name to Inovio Biomedical Corporation in March 2005. The company was founded in 1983 and is based in San Diego, California.

Currently Inovio has 12 clinical studies ( HIV, Influenza, Malaria, Hepatitis B, Hepatitis C, Breast and Lung cancer, Prostate Cancer, Head and Neck cancer, Cervical Cancer, Cervical dysplasia caused by HPV) ongoing from preclinical to phase 2.
Sep 10, 2013
Roche and Inovio Pharmaceuticals partner on Inovio's prostate cancer and hepatitis B immunotherapy products. Roche will make an upfront payment of USD $10 million to Inovio. Roche will also provide preclinical R&D support and payments for near-term regulatory milestones as well as payments upon reaching certain development and commercial milestones potentially up to USD $412.5 million. Additional development milestone payments could also be made to Inovio if Roche pursues other indications with INO-5150 or INO-1800.  In addition, Inovio is entitled to receive up to double-digit tiered royalties on product sales.

VGX-3100-Phase 2 Clinical Trial initiated for the treatment Cervical dysplasia (cervical intraepithelial neoplasia or CIN) caused by HPV
Top line data release Mid 2014
May 13, 2014:  Inovio Pharmaceuticals Acquires Early Stage DNA Therapies to Treat Alzheimer's and Multiple Sclerosis

May 23, 2014: Inovio Pharmaceuticals Announces 1 For 4 Reverse Split
1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.

Inovio’s goal is to revolutionize vaccines. With best-in-class immune responses from multiple vaccines in different disease areas, our synthetic vaccine technology is making big strides toward this important goal.



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
News News Alert: Current Report Filing (8-k) 07/20/2017 05:24:19 PM
#4698  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 08/02/13 01:15:33 PM
#14020   * * $INO Video Chart 07-20-17 * * ClayTrader 07/20/17 05:12:18 PM
#14019   yup, short position now only harry crumb 07/20/17 12:46:49 PM
#14018   Inovio Pharmaceuticals (INO -7.7%) prices its public offering kpisme 07/20/17 10:35:07 AM
#14017   this is a short play to 5 again harry crumb 07/20/17 10:31:58 AM
#14016   "...ApolloBio License Agreement and the ApolloBio Equity Agreement fireopal 07/20/17 01:57:22 AM
#14015   shoulda held that short >> Inovio Announces Pricing fireopal 07/19/17 10:59:37 PM
#14014   know this stock so well that i decided fireopal 07/19/17 10:38:57 PM
#14013   PRELIMINARY PROSPECTUS - In addition to the 75M, fireopal 07/18/17 11:52:11 PM
#14012   2.9 million shares sold since March 31 "at ppnlf 07/18/17 07:22:52 PM
#14011   Ouch that hurt! Silvr Surfr 07/18/17 04:49:34 PM
#14010   Sheesh so much for Zack's latest pt and fireopal 07/18/17 04:42:30 PM
#14009   Net proceeds will be used for general corporate purposes. kpisme 07/18/17 04:41:17 PM
#14008   Offering 75 mil Crap TomP1 07/18/17 04:18:57 PM
#14007   Hovering in the 8 area is better then TomP1 07/14/17 04:20:31 PM
#14006   Nice move INO with License agreement with Apollo! Stock Silvr Surfr 07/14/17 09:59:41 AM
#14005   lol i hear ya but i think Zack's fireopal 07/11/17 11:31:45 PM
#14004   Forget Zack's, I like the average analysts price radly 07/11/17 10:47:48 PM
#14003   Might be getting much closer to your $9 fireopal 07/11/17 06:50:16 PM
#14002   This stock just can't stay above $8/share can radly 07/10/17 03:56:41 PM
#14000   I, myself, have never seen an article signed/authored Ubertino 06/20/17 01:20:33 PM
#13999   LOL - NOTE the URL address - fireopal 06/20/17 01:05:40 PM
#13998   The article you link is by a law MiamiGent 06/20/17 12:51:45 PM
#13997   rotfl >> WAS NOT THE POINT. SO again, fireopal 06/20/17 12:38:51 PM
#13996   Of course the share price went up, as usual! Ubertino 06/20/17 09:30:06 AM
#13995   Caution: Inovio (INO) the king of PRs and MiamiGent 06/20/17 08:39:19 AM
#13994   It lists Inovio's (INO) pre-clinical testing in pigs MiamiGent 06/20/17 08:25:59 AM
#13993   INO Harvard University - highly unlikely for an fireopal 06/20/17 01:51:26 AM
#13992   INO PR MiamiGent 06/19/17 12:52:06 PM
#13991   Again - Not Kim. Additionally, vaccine development etc fireopal 06/19/17 09:17:48 AM
#13990   9/14/08 "INO Achieves 75% Complete Response Rate in MiamiGent 06/18/17 08:26:22 PM
#13988   All with great success! Ubertino 06/17/17 10:05:24 AM
#13987   Oh, I can easily oblige that request. Under MiamiGent 06/16/17 04:57:47 PM
#13986   Imo, is a good practice to post current fireopal 06/16/17 04:54:19 PM
#13985   Oh there are plenty more subsequent hyping PRs MiamiGent 06/16/17 04:27:23 PM
#13984   That PR is from 6/08 & Kim was fireopal 06/16/17 04:20:18 PM
#13983   Just a little bit hyperbole TomP1 06/16/17 04:09:19 PM
#13982   Kim will one day get the Nobel prize Ubertino 06/16/17 03:06:18 PM
#13981   added 20k to position harry crumb 06/16/17 01:58:50 PM
#13980   And those fly-by-night associates like Medimunne and Roche! Ubertino 06/16/17 09:55:41 AM
#13979   Here's one of Inovio's scores of hyping PRs- MiamiGent 06/15/17 11:21:30 PM
#13978   Dr Kim is not really running INO- the MiamiGent 06/15/17 02:09:58 PM
#13977   The run ups characterized by distorted and flat MiamiGent 06/15/17 02:02:15 PM
#13976   Good luck. TomP1 06/15/17 02:01:04 PM
#13975   "partnerships" misrepresented, a plethora of P1's & finally MiamiGent 06/15/17 01:59:38 PM
#13974   As for losing money, I am happy with TomP1 06/15/17 01:52:46 PM
#13973   Somehow everything is thrown onto one pile and TomP1 06/15/17 01:50:16 PM
#13972   The Director running INO is a penny stock MiamiGent 06/15/17 01:46:43 PM
#13971   Jim Cramers most recent interview with dr Kim TomP1 06/14/17 10:27:11 AM
#13970   It takes DD to find these things out. MiamiGent 06/14/17 10:08:56 AM
#13967   Did you miss the part about, "in the MiamiGent 06/14/17 09:09:25 AM